The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 18 January 2005, www.theannals.com, DOI 10.1345/aph.1E334.
 The Annals of Pharmacotherapy: Vol. 39, No. 3, pp. 502-507. DOI 10.1345/aph.1E334
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldman-Levine, J. D
Right arrow Articles by Lee, K. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldman-Levine, J. D
Right arrow Articles by Lee, K. W

NEW DRUG DEVELOPMENTS

Insulin Detemir—A New Basal Insulin Analog

Jennifer D Goldman-Levine, PharmD CDE

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, School of Pharmacy—Boston, Massachusetts College of Pharmacy and Health Sciences; Clinical Pharmacy Faculty, Certified Diabetes Educator, Tufts University Family Medicine Residency Program, Boston, MA

Karen W Lee, PharmD BSChem CDM

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, School of Pharmacy—Boston, Massachusetts College of Pharmacy and Health Sciences; Walgreens/MCPHS Community Pharmacy Practice Residency Program, Boston

Reprints: Dr. Goldman-Levine, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave., Boston, MA 02115-5804, fax 617/732-2244, jgoldman-levine{at}bos.mcphs.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trial data, adverse effects, and role in therapy of insulin detemir.

DATA SOURCES: Articles and meeting abstracts were identified through searches of MEDLINE (1996–June 2004), EMBASE (1980–June 2004), and International Pharmaceutical Abstracts (1970–June 2004) databases, and unpublished information was provided by the manufacturer.

STUDY SELECTION AND DATA EXTRACTION: All available studies relating to insulin detemir's pharmacology were selected. Only human studies were used for pharmacokinetic, drug interaction, efficacy, and safety data.

DATA SYNTHESIS: Insulin detemir is a basal insulin analog that has been shown to improve glycemic control in patients with type 1 and type 2 diabetes.

CONCLUSIONS: Insulin detemir offers some benefits over NPH for use as basal insulin in patients with type 1 and type 2 diabetes.

Key Words: basal insulin, detemir, Levemir, NN304

Published Online, January 18, 2005. www.theannals.com, DOI 10.1345/aph.1E334

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-011-H01


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. C. Jones and M. Patel
Insulin detemir: A long-acting insulin product
Am. J. Health Syst. Pharm., December 15, 2006; 63(24): 2466 - 2472.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
F. M Regan and D. B Dunger
Use of new insulins in children
Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.